AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27

Cancer Research

Volumn 68, Issue 16, 2008, Pages 6496-6506

  Short, John D ^a   Houston, Kevin D ^a   Dere, Ruhee ^a   Cai, Sheng Li ^a   Kim, Jinhee ^a   Johnson, Charles L ^a   Broaddus, Russell R ^b   Shen, Jianjun ^a   Miyamoto, Susie ^d   Tamanoi, Fuyuhiko ^d   Kwiatkowski, David ^e   Mills, Gordon B ^c   Walker, Cheryl Lyn ^a,c  

^a Departments of Carcinogenesis

^b Departments of Molecular Pathology   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; CYCLIN DEPENDENT KINASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN INHIBITOR; PROTEIN KINASE LKB1; PROTEIN P27; AMP ACTIVATED PROTEIN KINASES; AMP-ACTIVATED PROTEIN KINASES; CDKN1B PROTEIN, MOUSE; CDKN1B PROTEIN, RAT; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MULTIENZYME COMPLEX; PROTEIN SERINE THREONINE KINASE; TUBERIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL CYCLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; EMBRYO; ENERGY BALANCE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; TSC2 GENE; TUMOR SUPPRESSOR GENE; ANIMAL; CELL CULTURE; CELL FRACTIONATION; CYTOSOL; KIDNEY; METABOLISM; MOUSE MUTANT; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL NUCLEUS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; CYTOSOL; HUMANS; KIDNEY; MALE; MICE; MICE, KNOCKOUT; MULTIENZYME COMPLEXES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; SIGNAL TRANSDUCTION; SUBCELLULAR FRACTIONS; TUMOR SUPPRESSOR PROTEINS;

EID: 53049083680     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5756     Document Type: Article

References (38)

1. Gomez MR, Sampson JR, Whittemore VH, editors. Tuberous sclerosis complex. 3rd ed. Oxford: Oxford University Press; 1999.
2. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2005;14 Spec No. 2:R251-8.
3. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-56.
4. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004;166:213-23.
5. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 2005;19:1773-8.
6. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004;14:1650-6.
7. Zhang H, Cicchetti G, Onda H, et al. Loss of Tscl/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through down-regulation of PDGFR. J Clin Invest 2003; 112:1223-33.
8. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 2004;29:18-24.
9. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115:577-90.
10. Rosner M, Freilinger A, Hengstschlager M. The tuberous sclerosis genes and regulation of the cyclindependent kinase inhibitor p27. Mutat Res 2006;613:10-6.
11. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10-7.
12. Hengst L. A second RING to destroy p27(Kip1). Nat Cell Biol 2004;6:1153-5.
13. Rosner M, Freilinger A, Hanneder M, et al. p27Kipl localization depends on the tumor suppressor protein tuberin. Hum Mol Genet 2007;16:1541-56.
14. Rosner M, Hengstschlager M. Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J Biol Chem 2004;279:48707-15.
15. Soucek T, Yeung RS, Hengstschlager M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci U S A 1998;95:15653-8.
16. Hahn-Windgassen A, Nogueira V. Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005;280:32081-9.
17. Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007;9:218-24.
18. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kipl is haplo-insufficient for tumour suppression. Nature 1998;396:177-80.
19. +/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999;104:687-95.
20. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 1995;146:1568-79.
21. Walker C, Goldsworthy TL, Wolf DC, Everitt J. Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. Science 1992;255:1693-5.
22. Cai SL, Tee AR, Short JD, et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 2006;173:279-89.
23. Walker CL, Hunter D, Everitt JI. Uterine leiomyoma in the Eker rat: a unique model for important diseases of women. Genes Chromosomes Cancer 2003;38:349-56.
24. Sapkota GP, Kieloch A, Lizcano JM, et al. Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell growth. J Biol Chem 2001;276:19469-82.
25. Ouedraogo R, Wu X, Xu SQ, et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 2006;55:1840-6.
26. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74.
27. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6:91-9.
28. Wu FY, Wang SE, Sanders ME, et al. Reduction of cytosolic p27(Kipl) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res 2006;66:2162-72.
29. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclindependent kinase inhibitor function of p27(Kip1). Cell 1996;85:721-32.
30. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999;59:1206-11.
31. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 2003;278:39422-7.
32. Finlay GA, Thannickal VJ, Fanburg BL, Kwiatkowski DJ. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin. Cancer Res 2005;65:10881-90.
33. Govindarajan B, Brat DJ, Csete M, et al. Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. J Biol Chem 2005;280:5870-4.
34. Choi SL, Kim SJ, Lee KT, et al. The regulation of AMP-activated protein kinase by H(2)O(2). Biochem Biophys Res Commun 2001;287:92-7.
35. Soucek T, Rosner M, Miloloza A, et al. Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression. Oncogene 2001; 20:4904-9.
36. Borriello A, Cucciolla V, Oliva A, Zappia V, Delia Ragione F. p27Kipl metabolism: a fascinating labyrinth. Cell Cycle 2007;6:1053-61.
37. Besson A, Hwang HC, Cicero S, et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007;21:1731-46.
38. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-34.